Cancer Research and Treatment

Original Articles

Efficacy and Safety of Ropeginterferon Alfa-2b in Low-Risk Polycythemia Vera: Ji Yun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Sang Kyun Sohn, Seug Yun Yoon, Soo-Mee Bang, Gyeong-Won Lee, Chul Won Choi, Eun-Ji Choi, June-Won Cheong, Young Hoon Park, Sung-Eun Lee; Received May 23, 2025 Accepted June 25, 2025 Published online June 26, 2025; DOI: https://doi.org/10.4143/crt.2025.552 [Epub ahead of print]

Abstract PDF Supplementary Material PubReader ePub

Purpose
Conventional management of low-risk polycythemia vera (PV), consisting of phlebotomy and aspirin, often fails to adequately control symptoms and hematologic parameters. This study evaluated the efficacy and safety of ropeginterferon alfa-2b (Ropeg) in low-risk PV patients requiring cytoreductive therapy.
Materials and Methods
In this sub-analysis of an open-label, multicenter trial, 42 patients received Ropeg for 48 weeks. The primary endpoint was a reduction in phlebotomy frequency, while secondary endpoints included complete hematologic response (CHR), changes in JAK2V617F allele burden, and safety.
Results
Among 42 patients, Ropeg significantly reduced mean phlebotomy frequency per year from 3.0 to 0.5 (p < 0.05) and improved CHR rates (69.1% at 48 weeks). The JAK2V617F allele burden decreased, and hydroxyurea-naïve patients showed better responses. The most frequently reported treatment-related adverse events included elevated liver enzymes and alopecia. Most adverse events were mild or moderate, with no grade 4 or 5 events reported.
Conclusion
These findings suggest that Ropeg is a promising treatment option for low-risk PV by effectively reducing the need for phlebotomy and demonstrating efficacy and safety.

Citations

Citations to this article as recorded by

Two Decades of Real-World Data Reveals: Vigilance Signals of Drug-Induced Gingival Bleeding
Bozhao Wang, Xiaodong Chen, Deli Niu, Yuru Wang, Yuanyuan Zhang, Jian Li
International Dental Journal.2026; 76(2): 109409. CrossRef
Modern and multidisciplinary care in polycythemia vera
Francesca Palandri, Chiara Sartor, Alessandro Pileri, Olga Addimanda, Christian Gagliardi, Michelangelo Sartori, Monica Benni, Maddalena Giannella, Federica Lo Dato, Elena Sabattini, Lorenzo Fiorino, Alessandra Dedola, Filippo Branzanti, Maria B. Rondinel
Annals of Hematology.2026;[Epub] CrossRef

2,620 View
243 Download
2 Crossref

Hematologic malignancy

Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia: Seo-Yeon Ahn, TaeHyung Kim, Mihee Kim, Ga-Young Song, Sung-Hoon Jung, Deok-Hwan Yang, Je-Jung Lee, Mi Yeon Kim, Chul Won Jung, Jun-Ho Jang, Hee Je Kim, Joon Ho Moon, Sang Kyun Sohn, Jong-Ho Won, Sung-Hyun Kim, Hyeoung-Joon Kim, Jae-Sook Ahn, Dennis Dong Hwan Kim; Cancer Res Treat. 2023;55(3):1011-1022. Published online January 26, 2023; DOI: https://doi.org/10.4143/crt.2022.1407

Abstract PDF PubReader ePub

Purpose
We evaluated the characteristics of CCAAT/enhancer-binding protein α (CEBPA) mutations and the significance of a basic leucine zipper in-frame mutation (bZIP^in-f) of CEBPA in patients with acute myeloid leukemia with a normal karyotype.
Materials and Methods
Based on updated knowledge of CEBPA mutations, we conducted next-generation sequencing analyses in a previously established real-world cohort.
Results
Among 78 of a total of 395 patients (19.7%), 50 had bZIP^in-f CEBPA, and 28 had non-bZIP^in-f CEBPA. In the multivariate analysis, patients with NPM1^mut, those with bZIP^in-f CEBPA, and those who underwent allogeneic hematopoietic cell transplantation (allo-HCT) had favorable overall survival (OS), but FLT3-ITD^mut was a poor prognostic indicator. For relapse-free survival (RFS) and cumulative incidence of relapse, bZIP^in-f CEBPA, and allo-HCT were associated with favorable outcomes; FLT3-ITD^pos was associated with worse outcomes. In the CEBPA double-mutated group (CEBPA^dm), bZIP^in-f CEBPA was associated with superior outcomes in terms of OS (p=0.007) and RFS (p=0.007) compared with non-bZIP^in-f CEBPA. Of 50 patients with bZIP^in-f CEBPA, 36 patients had at least one mutation. When grouped by the presence of mutations in chromatic/DNA modifiers (C), cohesion complex (C), and splicing genes (S) (CCS mutations), CCS-mutated bZIP^in-f CEBPA was associated with poor OS (p=0.044; hazard ratio [HR], 2.419) and a trend in inferior RFS (p=0.186; HR, 1.838).
Conclusion
Only bZIP^in-f CEBPA was associated with favorable outcomes in patients with CEBPA^dm. However, some mutations accompanying bZIP^in-f CEBPA showed inferior OS; thus, further studies with larger numbers of patients are required for clear conclusions of the significance of bZIP^in-f CEBPA.

Citations

Citations to this article as recorded by

Prognostic value of CEBPA bZIP signatures in cytogenetically normal acute myeloid leukaemia
Li‐Xin Wu, Ming‐Yue Liao, Ming‐Yue Zhao, Nan Yan, Ping Zhang, Li‐Xia Liu, Jia‐Yue Qin, Shan‐Bo Cao, Jia Feng, Qian Jiang, Ying‐Jun Chang, Lan‐Ping Xu, Xiao‐Hui Zhang, Xiao‐Jun Huang, Hao Jiang, Hong‐Yu Zhang, Guo‐Rui Ruan
British Journal of Haematology.2026; 208(1): 170. CrossRef
CEBPA double mutations associated with ABO antigen weakness in hematologic diseases
Seung Jun Choi, Hyun Kyung Kim, Eun Jung Suh, Soon Sung Kwon, Saeam Shin, Seung-Tae Lee, Sinyoung Kim
Blood Advances.2024; 8(6): 1487. CrossRef
CEBPA bZIP in-frame mutations in acute myeloid leukemia: prognostic and therapeutic implications
Fenghong Zhang, Zhen Shen, Jundan Xie, Jingren Zhang, Qian Wu, Rui Jiang, Xiangyu Zhao, Xiaofei Yang, Suning Chen
Blood Cancer Journal.2024;[Epub] CrossRef
Mutations in the bZip region of the CEBPA gene: A novel prognostic factor in patients with acute myeloid leukemia
Juan Carlos Rivera, Daniel Nuñez, Elizabet Millar, Kimberly Ramirez, Mauricio Chandía, Claudio Aguayo
International Journal of Laboratory Hematology.2023; 45(6): 833. CrossRef

8,628 View
267 Download
5 Web of Science
4 Crossref

Clinical Outcome of Rituximab-Based Therapy (RCHOP) in Diffuse Large B-Cell Lymphoma Patients with Bone Marrow Involvement: Byung Woog Kang, Joon Ho Moon, Yee Soo Chae, Soo Jung Lee, Jong Gwang Kim, Yeo-Kyeoung Kim, Je-Jung Lee, Deok-Hwan Yang, Hyeoung-Joon Kim, Jin Young Kim, Young Rok Do, Keon Uk Park, Hong Suk Song, Ki Young Kwon, Min Kyung Kim, Kyung Hee Lee, Myung Soo Hyun, Hun Mo Ryoo, Sung Hwa Bae, Hwak Kim, Sang Kyun Sohn; Cancer Res Treat. 2013;45(2):112-117. Published online June 30, 2013; DOI: https://doi.org/10.4143/crt.2013.45.2.112

Abstract PDF PubReader ePub

PURPOSE
We investigated the clinical outcome of bone marrow (BM) involvement in patients with diffuse large B-cell lymphoma (DLBCL) who received rituximab-based therapy.
MATERIALS AND METHODS
A total of 567 consecutive patients with newly diagnosed DLBCL treated with rituximab-CHOP (RCHOP) between November 2001 and March 2010 were included in the current study. All of the patients underwent a BM study at the initial staging and the clinical characteristics and prognosis of these patients with or without BM involvement were analyzed retrospectively.
RESULTS
The total cohort included 567 patients. The overall incidence of BM involvement was 8.5%. With a median follow-up duration of 33.2 months (range, 0.1 to 80.7 months) for patients who were alive at the last follow-up, the five-year overall survival (OS) and event-free survival (EFS) rate in patients without BM involvement (76.3% and 67.5%, p<0.001) was statistically higher than that in patients with BM involvement (44.3% and 40.1%, p<0.001). In multivariate analysis, among total patients, BM involvement showed a significant association with OS and EFS. In univariate and multivariate analyses, even among stage IV patients, a significant association with worse EFS was observed in the BM involvement group.
CONCLUSION
BM involvement at diagnosis affected the survival of patients with DLBCL who received RCHOP. Although use of RCHOP can result in significant improvement of the therapeutic effect of DLBCL, BM involvement is still a negative prognostic factor of DLBCL patients in the era of rituximab.

Citations

Citations to this article as recorded by

Combination of Bone Marrow Biopsy and Flow Cytometric Analysis: The Prognostically Relevant Central Approach for Detecting Bone Marrow Invasion in Diffuse Large B-Cell Lymphoma
Haruya Okamoto, Nobuhiko Uoshima, Ayako Muramatsu, Reiko Isa, Takahiro Fujino, Yayoi Matsumura-Kimoto, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Tsutomu Kobayashi, Eri Kawata, Hitoji Uchiyama, Junya Kuroda
Diagnostics.2021; 11(9): 1724. CrossRef
Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility
Jeffrey W. Craig, Michael J. Mina, Jennifer L. Crombie, Ann S. LaCasce, David M. Weinstock, Geraldine S. Pinkus, Olga Pozdnyakova, Francesco Bertolini
PLOS ONE.2018; 13(7): e0199708. CrossRef
HIV-infection impact on clinical–biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era
Maria Joao Baptista, Olga Garcia, Mireia Morgades, Eva Gonzalez-Barca, Pilar Miralles, Armando Lopez-Guillermo, Eugenia Abella, Miriam Moreno, Juan-Manuel Sancho, Evarist Feliu, Josep-Maria Ribera, Jose-Tomas Navarro
AIDS.2015; 29(7): 811. CrossRef
Non-Hodgkin Lymphomas: Impact of Rituximab on Overall Survival of Patients with Diffuse Large B-Cell and Follicular Lymphoma
José Carlos Jaime-Pérez, Carmen Magdalena Gamboa-Alonso, Alberto Vázquez-Mellado de Larracoechea, Marisol Rodríguez-Martínez, César Homero Gutiérrez-Aguirre, Luis Javier Marfil-Rivera, David Gómez-Almaguer
Archives of Medical Research.2015; 46(6): 454. CrossRef

26,952 View
64 Download
4 Crossref

Prognostic Impact of Polymorphisms in the CASPASE Genes on Survival of Patients with Colorectal Cancer: Jun Young Choi, Jong Gwang Kim, You Jin Lee, Yee Soo Chae, Sang Kyun Sohn, Joon Ho Moon, Byung Woog Kang, Min Kyu Jung, Seong Woo Jeon, Jun Seok Park, Gyu Seog Choi; Cancer Res Treat. 2012;44(1):32-36. Published online March 31, 2012; DOI: https://doi.org/10.4143/crt.2012.44.1.32

Abstract PDF PubReader ePub

PURPOSE
This study analyzed potentially functional polymorphisms in CASPASE (CASP) genes and their impact on the prognosis for Korean colorectal cancer patients.
MATERIALS AND METHODS
A total of 397 consecutive patients with curatively resected colorectal adenocarcinoma were enrolled in this study. Genomic DNA from these patients was extracted from fresh colorectal tissue, and the 10 polymorphisms in the CASP3, CASP6, CASP7, CASP8, CASP9, and CASP10 genes were determined using a reverse transcription polymerase chain reaction genotyping assay.
RESULTS
The median patient age was 63 years, and 218 (54.9%) patients had colon cancer, while 179 (45.1%) patients had rectal cancer. Univariate and multivariate survival analysis including pathologic stage, patient age, differentiation, and carcinoembryonic antigen level demonstrated that these polymorphisms were not associated with either disease-free or overall survival.
CONCLUSION
None of the 10 polymorphisms in the CASP genes investigated in this study was found to be an independent prognostic marker for Korean patients with curatively resected colorectal cancer.

Citations

Citations to this article as recorded by

Immune-related gene-based model predicts the survival of colorectal carcinoma and reflected various biological statuses
Zhengchun Kang, Bingchen Chen, Xiuzhu Ma, Feihu Yan, Zhen Wang
Frontiers in Molecular Biosciences.2023;[Epub] CrossRef
TCGA dataset screening for genes implicated in endometrial cancer using RNA-seq profiling
Xiaoli Fu, Shuai Cheng, Wei Wang, Oumin Shi, Fuxiao Gao, Yong Li, Qi Wang
Cancer Genetics.2021; 254-255: 40. CrossRef
Mutational analysis of apoptotic genes in familial aggregation of hematological malignancies
Walid Sabri Hamadou, Rahma Mani, Nouha Bouali, Sawsen Besbes, Violaine Bourdon, Rym El Abed, Yosra Ben Youssef, Véronique Mari, Paul Gesta, Hélène Dreyfus, Valérie Bonadona, Catherine Dugast, Hélène Zattara, Laurence Faivre, Tetsuro Noguchi, Abderrahim Kh
Bulletin du Cancer.2021; 108(9): 798. CrossRef
Construction and Characterization of a Synergistic lncRNA–miRNA Network Reveals a Crucial and Prognostic Role of lncRNAs in Colon Cancer
Bin Zhao, Xiusheng Qu, Xin Lv, Qingdong Wang, Deqiang Bian, Fan Yang, Xingwang Zhao, Zhiwu Ji, Jian Ni, Yan Fu, Guorong Xin, Haitao Yu
Frontiers in Genetics.2020;[Epub] CrossRef
CASP8 (rs3834129) and CASP3 (rs4647601) polymorphisms in oropharynx cancer risk, tumor cell differentiation, and prognosis in a cohort of the Brazilian population
Gabriela Arielo Tortorelli, Caroline Torricelli, Juliana Carron, Ericka Francislaine Dias Costa, Leisa Lopes-Aguiar, Bruna Fernandes Carvalho, José Augusto Rinck-Junior, Fernanda Viviane Mariano, Albina Messias Almeida Milani Altemani, Carmen Silvia Passo
Molecular Biology Reports.2019; 46(6): 6557. CrossRef
Screening for implicated genes in colorectal cancer using whole‑genome gene expression profiling
Long‑Ci Sun, Hai‑Xin Qian
Molecular Medicine Reports.2018;[Epub] CrossRef
Apoptosis-inducing and antiproliferative effect by inhibition of miR-182-5p through the regulation of CASP9 expression in human breast cancer
M Sharifi, A Moridnia
Cancer Gene Therapy.2017; 24(2): 75. CrossRef
Inducing cell proliferative prevention in human acute promyelocytic leukemia by miR-182 inhibition through modulation of CASP9 expression
Mahdi Fasihi-Ramandi, Abbas Moridnia, Ali Najafi, Mohammadreza Sharifi
Biomedicine & Pharmacotherapy.2017; 89: 1152. CrossRef
Genetic variants in cell death pathway genes and HBV-related hepatocellular carcinoma among a Chinese Han population
Fei Liu, Fuqiang Li, Limei Luo, Hanteng Yang, Yonggang Wei, Wentao Wang, Lvnan Yan, Tianfu Wen, Jiayin Yang, Bo Li
Apoptosis.2017; 22(8): 1035. CrossRef
Associations of genetic variation in CASP3 gene with noise-induced hearing loss in a Chinese population: a case–control study
Yinyin Wu, Juntao Ni, Mingjian Qi, Chengjian Cao, Yuxian Shao, Liangwen Xu, Haiyan Ma, Lei Yang
Environmental Health.2017;[Epub] CrossRef
CASP8-652 6N insertion/deletion polymorphism and overall cancer risk: evidence from 49 studies
Jiarong Cai, Qingjian Ye, Suling Luo, Ze Zhuang, Kui He, Zhen-Jian Zhuo, Xiaochun Wan, Juan Cheng
Oncotarget.2017; 8(34): 56780. CrossRef
Association between main Caspase Gene Polymorphisms and the Susceptibility and Prognosis of Colorectal Cancer
Zhiwei Wu, Ye Li, Shuying Li, Lin Zhu, Guangxiao Li, Zhifu Yu, Xiaojuan Zhao, Jie Ge, Binbin Cui, Xinshu Dong, Suli Tian, Fulan Hu, Yashuang Zhao
Medical Oncology.2013;[Epub] CrossRef

13,288 View
60 Download
12 Crossref

No Association of Insulin-like Growth Factor Gene Polymorphisms with Survival in Patients with Colorectal Cancer: Yoon Young Cho, Jong Gwang Kim, Yee Soo Chae, Sang Kyun Sohn, Byung Woog Kang, Joon Ho Moon, Seong Woo Jeon, Jun Seok Park, Jin Young Park, Gyu Seog Choi; Cancer Res Treat. 2011;43(3):189-194. Published online September 30, 2011; DOI: https://doi.org/10.4143/crt.2011.43.3.189

Abstract PDF PubReader ePub

PURPOSE
Insulin-like growth factors (IGF) regulate a wide range of biological functions including cell proliferation, differentiation, and apoptosis through paracrine and autocrine mechanisms. Accordingly, the present study analyzed polymorphisms of IGF genes and their impact on the prognosis for patients with colorectal cancer.
MATERIALS AND METHODS
Four hundred and two consecutive patients with curatively resected colorectal adenocarcinoma were enrolled in the present study. The genomic DNA was extracted from fresh colorectal tissue and 8 polymorphisms of IGF genes determined using a real-time polymerase chain reaction genotyping assay.
RESULTS
Pathologic stages after surgery were as follows: stage 0/I (n=85, 21.1%), stage II (n=147, 36.6%), stage III (n=145, 36.1%), and stage IV (n=25, 6.2%). Multivariate survival analysis including stage, age, site of disease, and carcinoembryonic antigen level showed that the progression-free survival for patients with the IGF2 +1280 GG genotype was slightly better than for the patients with the combined IGF2 +1280 AA and AG genotype (p=0.056), although there was no significant difference in the overall survival. However, the other polymorphisms were not associated with survival.
CONCLUSION
None of the 8 IGF1 or IGF2 gene polymorphisms investigated in this study were found to be independent prognostic markers for Korean patients with surgically resected colorectal cancer.

Citations

Citations to this article as recorded by

A systematic review and meta-analysis for the association of the insulin-like growth factor1 pathway genetic polymorphisms with colorectal cancer susceptibility
Makan Cheraghpour, Masomeh Askari, Sascha Tierling, Sajad Shojaee, Amir Sadeghi, Pardis Ketabi Moghadam, Maryam Khazdouz, Hamid Asadzadeh Aghdaei, Moein Piroozkhah, Ehsan Nazemalhosseini-Mojarad, Nayeralsadat Fatemi
Frontiers in Oncology.2023;[Epub] CrossRef
Association of metabolic syndromes and risk factors with ampullary tumors development: A case-control study in China
Xiao-Dong He, Qiao Wu, Wei Liu, Tao Hong, Jing-Jing Li, Ruo-Yu Miao, Hai-Tao Zhao
World Journal of Gastroenterology.2014; 20(28): 9541. CrossRef
Clinical significance of insulin-like growth factor gene polymorphisms with survival in patients with gastrointestinal stromal tumors
Ohkyoung Kwon, Ho Young Chung, Wansik Yu, Han Ik Bae, Yee Soo Chae, Jong Gwang Kim, Byung Woog Kang, Won Ki Lee
Journal of the Korean Surgical Society.2012; 82(5): 288. CrossRef

12,244 View
54 Download
3 Crossref

No Association of Vascular Endothelial Growth Factor-A (VEGF-A) and VEGF-C Expression with Survival in Patients with Gastric Cancer: Soo Jung Lee, Jong Gwang Kim, Sang Kyun Sohn, Yee Soo Chae, Joon Ho Moon, Shi Nae Kim, Han-Ik Bae, Ho Young Chung, Wansik Yu; Cancer Res Treat. 2009;41(4):218-223. Published online December 31, 2009; DOI: https://doi.org/10.4143/crt.2009.41.4.218

Abstract PDF PubReader ePub

Purpose

Although the vascular endothelial growth factor (VEGF) superfamily has been identified to critically influence tumor-related angiogenesis, the prognostic significance of a VEGF expression in gastric cancer is still controversial. Accordingly, the present study analyzed the VEGF-A and VEGF-C expressions and their impact on the prognosis of patients with gastric cancer.

Materials and Methods

Three hundred seventy-five consecutive patients who underwent surgical resection for gastric adenocarcinoma with a curative intent were enrolled in the present study. Immunohistochemical staining for VEGF-A and VEGF-C was performed using the formalin fixed, paraffin embedded tumor tissues.

Results

Positive VEGF-A and VEGF-C expressions were observed in 337 (90.1%) and 278 (74.9%) cases, respectively. The survival analysis showed that the expression of VEGF-A and VEGF-C had no effect on the OS and DFS. On the multivariate analysis that included age, gender and the TNM stage, no significant association between the grade of the VEGF-A or VEGF-C expression and survival was observed.

Conclusion

The current study suggests that the tissue expression of VEGF-A or VEGF-C alone is not an independent prognostic marker for patients with surgically resected gastric adenocarcinoma.

Citations

Citations to this article as recorded by

VEGF-C and Lymphatic Vessel Density in Tumor Tissue of Gastric Cancer: Correlations with Pathoclinical Features and Prognosis
Mariusz Szajewski, Maciej Ciesielski, Rafał Pęksa, Piotr Kurek, Michał Stańczak, Jakub Walczak, Jacek Zieliński, Wiesław Janusz Kruszewski
Cancers.2025; 17(9): 1406. CrossRef
Comparison of Vascular Endothelial Growth Factor C Expression with Lymph Node Metastasis Status and Survival in Gastric Cancer
Umut F. Turan, Tolga Dinc, Ilgaz Kayilioglu, Ayse Yilmaz-Ciftci, Faruk Coskun
European Surgical Research.2025; 66(1): 118. CrossRef
Proposed Molecular and miRNA Classification of Gastric Cancer
Lara Alessandrini, Melissa Manchi, Valli De Re, Riccardo Dolcetti, Vincenzo Canzonieri
International Journal of Molecular Sciences.2018; 19(6): 1683. CrossRef
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab
Charles S Fuchs, Josep Tabernero, Jiří Tomášek, Ian Chau, Bohuslav Melichar, Howard Safran, Mustapha A Tehfe, Dumitru Filip, Eldar Topuzov, Luis Schlittler, Anghel Adrian Udrea, William Campbell, Stephen Brincat, Michael Emig, Symantha A Melemed, Rebecca
British Journal of Cancer.2016; 115(8): 974. CrossRef
Fentanyl inhibits the progression of human gastric carcinoma MGC-803 cells by modulating NF-κB-dependent gene expression in vivo
GUODONG HE, LI LI, ENJIAN GUAN, JING CHEN, YI QIN, YUBO XIE
Oncology Letters.2016; 12(1): 563. CrossRef
Disrupted Balance of MMPs/TIMPs in Gastric Carcinogenesis–Paradoxical Low MMP-2 Expression in Tumor and Stromal Compartments as a Potential Marker of Unfavorable Outcome
Piotr Donizy, Julia Rudno-Rudzinska, Maciej Kaczorowski, Jedrzej Kabarowski, Ewelina Frejlich, Wojciech Kielan, Rafal Matkowski, Agnieszka Halon
Cancer Investigation.2015; 33(7): 286. CrossRef
The different role of intratumoral and peritumoral lymphangiogenesis in gastric cancer progression and prognosis
Kyung Ho Pak, Ara Jo, Hye Ji Choi, Younghee Choi, Hyunki Kim, Jae-Ho Cheong
BMC Cancer.2015;[Epub] CrossRef
Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy
Ismael Riquelme, Kathleen Saavedra, Jaime A. Espinoza, Helga Weber, Patricia García, Bruno Nervi, Marcelo Garrido, Alejandro H. Corvalán, Juan Carlos Roa, Carolina Bizama
Oncotarget.2015; 6(28): 24750. CrossRef
VEGF-C expression is associated with the poor survival in gastric cancer tissue
Weiguo Cao, Rong Fan, Weiping Yang, Yunlin Wu
Tumor Biology.2014; 35(4): 3377. CrossRef
VEGF-A clinical significance in gastric cancers: Immunohistochemical analysis of a wide Italian cohort
E. Lastraioli, L. Boni, M.R. Romoli, S. Crescioli, A. Taddei, S. Beghelli, A. Tomezzoli, C. Vindigni, L. Saragoni, L. Messerini, M. Bernini, L. Bencini, E. Giommoni, G. Freschi, F. Di Costanzo, A. Scarpa, P. Morgagni, M. Farsi, F. Roviello, G. De Manzoni,
European Journal of Surgical Oncology (EJSO).2014; 40(10): 1291. CrossRef
Prognostic value of vascular endothelial growth factor A expression in gastric cancer: a meta-analysis
Ya-nan Ji, Qin Wang, Yang Li, Zhi Wang
Tumor Biology.2014; 35(3): 2787. CrossRef
Clinicopathologic Significance of Nuclear Factor-κB and Vascular Endothelial Growth Factor Expression in Advanced Gastric Cancer Patients
Keon Woo Park, Su-Jin Kim, Sung Yong Oh
Oncology Research and Treatment.2014; 37(4): 183. CrossRef
Prognostic Value of Vascular Endothelial Growth Factor Expression in Resected Gastric Cancer
Lei Liu, Xue-Lei Ma, Zhi-Lan Xiao, Mei Li, Si-Hang Cheng, Yu-Quan Wei
Asian Pacific Journal of Cancer Prevention.2012; 13(7): 3089. CrossRef
Potential prognostic and therapeutic role for angiogenesis markers in laryngeal carcinoma
Marco Lionello, Alberto Staffieri, Gino Marioni
Acta Oto-Laryngologica.2012; 132(6): 574. CrossRef
Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis
Ling Peng, Ping Zhan, Yun Zhou, Weijia Fang, Peng Zhao, Yulong Zheng, Nong Xu
Molecular Biology Reports.2012; 39(10): 9473. CrossRef
Protein Kinase B Phosphorylation Correlates with Vascular Endothelial Growth Factor A and Microvessel Density in Gastric Adenocarcinoma
Xd Zhou, Hx Chen, Rn Guan, Yp Lei, X Shu, Y Zhu, Nh Lv
Journal of International Medical Research.2012; 40(6): 2124. CrossRef
Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis
Jing Chen, Tao Li, Yuanyuan Wu, Lijun He, Li Zhang, Tieliu Shi, Zhengfang Yi, Mingyao Liu, Xiufeng Pang
Journal of Cancer Research and Clinical Oncology.2011; 137(12): 1799. CrossRef
Vascularization of testicular germ cell tumours: evidence from experimental teratocarcinomas
U. Silván, A. Díez‐Torre, L. Jiménez‐Rojo, J. Aréchaga
International Journal of Andrology.2010; 33(6): 765. CrossRef
Cancer-associated fibroblasts are positively correlated with metastatic potential of human gastric cancers
Kangkang Zhi, Xiaojun Shen, Hao Zhang, Jianwei Bi
Journal of Experimental & Clinical Cancer Research.2010;[Epub] CrossRef

12,449 View
66 Download
19 Crossref

Hematologic malignancy

Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study: Jongheon Jung, Kihyun Kim, Sung-Hoon Jung, Sung-Soo Yoon, Jae Hoon Lee, Jin Seok Kim, Ho-Jin Shin, Soo-Mee Bang, Sang Kyun Sohn, Cheolwon Suh, Dok Hyun Yoon, Sun-Young Kong, Chang-Ki Min, Hyeon-Seok Eom, The Korean Multiple Myeloma Working Party; Cancer Res Treat. 2023;55(2):693-703.; DOI: https://doi.org/10.4143/crt.2022.952

Abstract PDF Supplementary Material PubReader ePub

Purpose
A three-drug combination of cyclophosphamide, bortezomib, and dexamethasone (CVD) shows significant efficacy and manageable toxicity as induction therapy in patients with multiple myeloma.
Materials and Methods
In this phase II study, we enrolled 45 patients who achieved a very good partial response (VGPR) or partial response (PR) after autologous stem cell transplantation (ASCT) and evaluated the efficacy and toxicity of CVD consolidation. CVD consolidation comprised three cycles of cyclophosphamide 300 mg/m² orally on days 1, 8, and 15, and bortezomib 1.3 mg/m² subcutaneously on days 1, 8, 15, and 22, along with dexamethasone 20 mg orally or intravenously on days 1 and 2, 8 and 9, 15 and 16, and 22 and 23.
Results
At enrollment, 39 patients (86.7%) showed VGPR, and nine (13.3%) presented with PR. Nineteen patients (45.2%) achieved a complete response or better as their best response after the end of consolidation. Overall, 22 of 42 patients (52.4%) experienced an improved response status with CVD consolidation. Three-year overall survival and progression-free survival rates were 89.0% and 42.7%, respectively. The most common non-hematologic toxicities were peripheral neuropathy and infection (20.5%), with no grade ≥ 3 neuropathy observed.
Conclusion
These results showed that CVD consolidation therapy improved the response with reasonable toxicity in patients with residual disease after ASCT. This trial was registered with the Clinical Research Information Service, Republic of Korea (KCT0001327).

Citations

Citations to this article as recorded by

Is Consolidation Therapy Effective in Multiple Myeloma Patients after High-Dose Chemotherapy and Autologous Stem Cell Transplantation: Single Center Real-Life Data with Cyclophosphamide-Bortezomib-Dexamethasone or Bortezomib-Lenalidomide-Dexamethasone?
Şeyma Yıldız, Asil Demirezen, Zeynep Arzu Yeğin, Münci Yağcı, Zübeyde Nur Özkurt
Indian Journal of Hematology and Blood Transfusion.2026; 42(3): 765. CrossRef
Kappa Light Chain-Restricted Multiple Myeloma with Biopsy-Proven Cast Nephropathy and Negative Bence–Jones Proteinuria: A Rare Clinical Presentation
Hamesh Gundala Raja, Manoj Sivakumar, Loveleen K Johal, Sumair Ali Khan, Fatimah Khan
Cureus.2025;[Epub] CrossRef
Is There Still a Role for Stem Cell Transplantation in Multiple Myeloma?
Morie A. Gertz
Hematology/Oncology Clinics of North America.2024; 38(2): 407. CrossRef
Ginsenoside Rg1 inhibits multiple myeloma and overcomes bortezomib resistance through AMPK-mTOR pathway
Li Lin, Dong Chen, Shuangyue Li, Tiantian Wang
Heliyon.2024; 10(13): e33935. CrossRef

8,634 View
175 Download
3 Web of Science
4 Crossref

A Clinical Study on Patients with Chronic Lymphocytic Leukemia: Jeon Ho Yang, Hyeon Soo Shin, Young Sik Jung, Jun Ho Whang, Dong Gun Shin, Sang Kyun Sohn, Kyu Bo Lee, Kee Suk Whang; J Korean Cancer Assoc. 1997;29(6):1106-1113.

Abstract PDF: PURPOSE
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in western countries but it has been reported rarely in Korea. The purpose of this study was to evaluate the clinical characteristics, treatment responses and prognosis of the patients with CLL.
MATERIALS AND METHODS
We retrospectively reviewed the medical records of 17 patients with CLL diagnosed at the Catholic University of Taegu-Hyosung & Kyungpook National University Hospital from Jan. 1986 to Mar. 1996.
RESULTS
There were 9 males and 8 females and the mean age was 55 years. The majority of patients had systemic symptoms (77%) and advanced clinical stage (Binet stage C, 70%) at the time of diagnosis. The bone marrow histology was reviewed in 13 cases and patients were subdivided into those with a diffuse (9cases) and nondiffuse (4cases) pattern of bone marrow histology. In patients with advanced clinical stage, diffuse pattern was predominated and showed poor survival. 14 patients were treated with chlorambucil/steroid or combination chemotherapy. Among the 13 evaluable patients, 1 (8%) achieved a complete response and 7 (54%) achieved partial responses, and median survival duration was 18months. 11 patients died after 2~18 months of follow-up and infection was the main cause of death.
CONCLUSION
Poor prognostic factors, such as high blood lymphocyte counts, diffuse bone marrow involvement pattern & advanced clinical stage, are common in our patients at presentation & showed poor survival.

3,229 View
18 Download

Effects of New Nultidrug - Resistance Reversing Agent, KR-30035, on Tumoral Uptake of Tc-99m MIBI In-vitro and In-vivo: Ihn Ho Cho, Jaetae Lee, Jang Soo Suh, Byung Ho Lee, Sang Woon Choi, Sang Kyun Sohn, Chong Ock Lee, Sung Eun Yoo, June Key Chung, Kyu Bo Lee; J Korean Cancer Assoc. 1999;31(4):773-783.

Abstract PDF: PURPOSE
Verapamil is one of the most extensively characterized modulators of P-glyco- protein (P-gp) mediated multi-drug resistance (MDR), but its plasma concentration required to reverse MDR can cause cardiovascular toxicity. KR-30035 is a newly synthesized verapamil analogue with more potent cytostatic effects, but has lower cardiovascular effects than verapamil. We have assessed the MDR reversing effects of KR-30035 by measuring Tc-99m MIBI uptake in cultured tumor cells and in nude mice bearing human tumor xenografts.
MATERIALS AND METHODS
In-vitro uptake of Tc-99m MIBI was measured in murine leukemia cells (L-1210) and those MDR-positive variants after incubation with different concentrations of KR-30035. Results were compared to those with verapamil. Organ and tumoral uptake of Tc-99m MIBI was compared between P-gp (+) human colon cancer (HCT15 cells) and P-gp (-) lung cancer (A549 cells) in nude mice, treated with either KR-30035 or verapamil.
RESULTS
There was no significant difference in in-vitro uptake of Tc-99m MIBI between verapamil and KR-30035 group at any concentrations. MIBI uptake in P-gp (+) cells continuously increased either with verapamil or KR-30035 in a dose-dependent manner. Tc-99m MIBI uptake ratios of the tumor [P-gp (+' tumor uptake divided by P-gp (-) uptake] were significantly higher with KR-30035 than with verapamil in tumor bearing nude mice. Washout rate of Tc-99m MIBI from P-gp (+) HCT15 cells was lower in verapamil or KR-30035 groups than in the control group, which was 0.19, 0.19 and 0.27 respectively.
CONCLUSION
These studies revealed that KR-30035 can potentially be used as an active modulator of MDR, with its significantly lesser cardiovascular toxicity than verapamil. Our results warrants further evaluation of this novel agent.

2,963 View
15 Download

Radioimmunotherapy for Lung Metastasis of MMTV-induced Breast Cancer in Mice with 131I-labeled Monoclonal Antibody: Sang Kyun Sohn, Jae Tae Lee, Chang Woon Choi, Tibor Bakacs, M . Belen Moreno, Byeong Cheol Ahn, Kyu Bo Lee, David Segal, Chang H . Paik; J Korean Cancer Assoc. 1996;28(3):472-483.

Abstract PDF: Radiolabeled monoclonal antibodies appear to be gaining a role in the management of cancer by means of imaging methods to detect sites of increased radioactivity, and several products have been developed and tested clinically. In the area of radioimmunotherapy, the radiolabeled monoclonal antibodies have shown the potentials in the treatment of the microtumors and metastases due to its inherited benefit from bystander effect of the ionizing radiation delivered with radioimmunoconjugates. We have evaluated the antitumor effects of I-131 labeled P2AE12 antibody, prepared against glycopratein of gp52 MMTV-induced murine mammary tumor cell, in allogeneic model of pulmonary metastatic cancer. The BALB/c normal mice were injected intravenously with 5 x 10(5) murine breast cancer cells and pulmonary metastases were acauired in all mice. Three days and ten days after tumor cell injection, each set of 250uCi of I-131 labeled antibody was injected in 15-20 mice for one or two treatment group. Survival of treatment group was compared with that of control group. One-treatment resulted in prolonged median survival of mice bearing metastases from 14(range: 13-16 days) to 16 days(range: 1422days), and two-treatments to 22(range: 20 to more than 40 days) days. Treatment with I-131 labeled P2AE12, antibody resulted in marked reduction of tumor burden in lung sections taken on days 7 and 14 days. Our results showed that radiolabeled monoclonal antibody can inhibit the growth of allogeneic solid tumor metastases in mice. Although it did not cure these kinds of aggressive metastatic tumors, these findings encourage the further evaluation of the radioimmunotherapy in pulmonary metastases with different schemes to enhance tumor uptake of radiolabeled antibody, as well as lessen the uptake in normal tissue.

2,686 View
12 Download

Case Report

A Case of Invasive Aspergillosis Characterized by the Formation of Large Bronchial Cast in Patient with Acute Myelogenous Leukemia: Dong Woo Hyun, Dong Hwan Kim, Jin Tae Jung, Sang Kyun Sohn, Kyu Bo Lee; J Korean Cancer Assoc. 1998;30(5):1021-1025.

Abstract PDF: Invasive aspergillosis is a life-threatening infectious disease in immunocompromised patients. Prolonged neutropenia is the most important predisposing factor. Bronchial casts are generally associated with pneumonia, bronchiectasis, asthma, chronic bronchitis, allergic bronchopulmonary aspergillosis and mucoviscidosis. We experienced.a case of invasive aspergillosis characterized by the formation of large bronchial cast in patient with acute myelogenous leukemia(AML) during induction chemotherapy. The patient expectorated a large bronchial cast without airway obstruction. Aspergillus was disclosed in intraluminal surface of bronchial cast. The patient's conditions improved after amphotericin B therapy and expectoration of a large bronchial cast.

2,732 View
14 Download

First
Prev
Page of 1
Next
Last

Search